A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients

被引：0
|
作者：
Haeberle, L. [1 ]
Erber, R. [2 ]
Gass, P. [1 ]
Hein, A. [1 ]
Jud, S. M. [1 ]
Langemann, H. [1 ]
Rauh, C. [1 ]
Hack, C. C. [1 ]
Schulz-Wendtland, R. [3 ]
Hartmann, A. [2 ]
Beckmann, M. W. [1 ]
Lux, M. P. [1 ]
Fasching, P. A. [1 ]
机构：
[1] Erlangen Univ Hosp, Dept Gynecol & Obstet, Erlangen, Germany
[2] Erlangen Univ Hosp, Inst Pathol, Erlangen, Germany
[3] Erlangen Univ Hosp, Inst Radiol, Erlangen, Germany
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
226P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer
    Matikas, A.
    Lovrot, J.
    Ramberg, A.
    Eriksson, M.
    Lindsten, T.
    Lekberg, T.
    Hedenfalk, I.
    Loman, N.
    Bergh, J.
    Erlandsson, A.
    Hatschek, T.
    Foukakis, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] Neoadjuvant Chemotherapy in Patients with HER2-Negative Breast Cancer: A Report from Clinical Breast Cancer Registry of Iran
    Roudini, Kamran
    Mirzania, Mehrzad
    Yavari, Tahereh
    Seyyedsalehi, Monireh Sadat
    Nahvijou, Azin
    Zebardast, Jayran
    Saadat, Mina
    Khajeh-Mehrizi, Ahmad
    ARCHIVES OF IRANIAN MEDICINE, 2024, 27 (04) : 206 - 215
  • [33] Complete pathological response in patients with locally advanced cancer of breast and positive Her2/neu with neoadjuvant chemotherapy
    Heidy Cedeño
    Rafael Araúz
    Fernando Cebamanos
    Idalmis de Torraza
    Ana Porcell
    BMC Cancer, 7 (Suppl 1)
  • [34] Multimodal machine learning model prediction of complete pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Groheux, David
    Ferrer, Loic
    Vargas, Jennifer
    Martineau, Antoine
    Teixeira, Luis
    Menu, Philippe
    Bertheau, Philippe
    Gallinato, Olivier
    Colin, Thierry
    Lehmann-Che, Jacqueline
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Multi-gene prognostic signatures and prediction of pathological complete response of ER-Positive HER2-negative breast cancer patients to neo-adjuvant chemotherapy
    Mazo, C.
    Barron, S.
    Mooney, C.
    Gallagher, W. M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] Prediction of pathological response to neoadjuvant chemotherapy in breast cancer patients by imaging
    Kaise, Hiroshi
    Shimizu, Fumika
    Akazawa, Kohei
    Hasegawa, Yoshie
    Horiguchi, Jun
    Miura, Daishu
    Kohno, Norio
    Ishikawa, Takashi
    JOURNAL OF SURGICAL RESEARCH, 2018, 225 : 175 - 180
  • [37] Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights
    Lucas, Mairi W.
    Kelly, Catherine M.
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2493 - 2506
  • [38] Improving pathological complete response in luminal breast cancer after neoadjuvant chemotherapy
    Cudos, Ariadna Gasol
    Murillo, Serafin Morales
    Galindo, Alvaro Rodriguez
    Subirats, Ona Pallise
    Olive, Jordi Mele
    Morales, Carles Canosa
    Villellas, Felip Vilardell
    Guzman, Douglas Rene Sanchez
    Rodriguez, Joel Veas
    CANCER RESEARCH, 2022, 82 (04)
  • [39] Pathological complete response (pCR) after neoadjuvant chemotherapy in luminal breast cancer
    Cordoba Ortega, J. F.
    Gasol Cudos, A.
    Morales Murillo, S.
    Vilardell Villellas, F.
    Siso Raber, C.
    Canosa Morales, C.
    Salud Salvia, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S313 - S313
  • [40] Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
    Dharanikota, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1482 - S1482
12345